This article was originally published in The Gray Sheet
Buyer is being sought for the firm's Analytical Instruments division following a review initiated in September 1998 to weigh strategic alternatives for the $600 mil.-a-year business ("The Gray Sheet" Sept. 14, 1998, p. 10). The AI unit markets a broad range of analytical chemistry systems used in clinical and biological analysis and in pharmaceutical development to identify and measure changes in properties of solids, liquids and gases. Perkin-Elmer would retain its $900 mil.-a-year PE Biosystems division and the newly formed Celera Genomics gene-based information joint venture with The Institute for Genomics Research
You may also be interested in...
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.
A few months after bringing AstraZeneca onboard as a partner, the turnaround at the Alderley Park-based firm is moving ahead, buoyed by a fresh financing.
2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.